Working to Eradicate Gynecologic Cancers

Scientific Plenary VII: Late Breaking Abstracts

Monday, March 30, 2015: 2:25 PM-3:45 PM
International Ballroom (Hilton Chicago)
Description: Scientific Plenary Session VII will address key advances in the management of ovarian cancers and endometrial cancers. Ovarian cancer topics covered will include the role of PARP inhibition, activity of tyrosine kinase treatment of clear cell cancers, the impact treatment in a cancer center on survival, a comparison of outcomes with primary surgery v. neoadjuvant chemotherapy, and the association of quality of life with outcomes in first line treatment. Endometrial cancer topics will include risk assessment for lymph node involvement prior to surgery, sentinel lymph node accuracy in high risk cancers, and results of oral multi-kinase antiangiogenic treatment of recurrent disease.
Moderators:  David E. Cohn, MD, The Ohio State University, Columbus, OH and Martee Leigh Hensley, MD, Weill Cornell Medical College, New York, NY
2:25 PM
Announcment of IMPROVING OUTCOMES IN GYNECOLOGIC ONCOLOGY PATIENTS RESEARCH AND EDUCATION AWARD, ME STRONG YOUNG INVESTIGATOR’S AWARD, SGO FELLOW-IN-TRAINING OVARIAN CANCER AWARD, WILMA WILLIAMS EDUCATION AND CLINICAL RESEARCH AWARD FOR ENDOMETRIAL CANCER
R. L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX
 
2:30 PM
Introductory Remarks
M. L. Hensley1 and D. E. Cohn2
1Weill Cornell Medical College, New York, NY, 2The Ohio State University, Columbus, OH
 
2:35 PM
Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: interim results for ARIEL2 clinical trial
E. M. Swisher1, A. M. Oza2, R. L. Coleman3, C. Scott4, K. Lin5, E. Dominy5, L. Maloney6, S. Goble6, R. Yelensky7 and I. McNeish8
1University of Washington, Seattle, WA, 2University Health Network, Princess Margaret Hospital, Toronto, ON, Canada, 3The University of Texas MD Anderson Cancer Center, Houston, TX, 4Royal Melbourne Hospital, Parkville Victoria, Australia, 5Clovis Oncology Inc., San Francisco, CA, 6Clovis Oncology Inc., Boulder, CO, 7Foundation Medicine Inc., Cambridge, MA, 8Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
 
2:44 PM
Preoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study): a Korean Gynecologic Oncology Group study
S. Kang1, J. H. Nam2, D. S. Bae3, J. W. Kim4, M. H. Kim5, X. Chen6, J. H. No7, J. M. Lee8, J. H. Kim9 and H. Watari10
1National Cancer Center, Ilsan, South Korea, 2University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea, 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Seoul National University, Seoul, South Korea, 5Korea Cancer Center Hospital, Goyang, South Korea, 6Fudan University Cancer Center, Shanghai, China, 7Seoul National University Bundang Hospital, Bundang, South Korea, 8Kyung Hee University East-West Neo Medical Center, Seoul, South Korea, 9Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 10Hokkaido University School of Medicine, Sapporo, Japan
 
2:53 PM
Sentinel lymph node mapping accurately identifies positive nodes in women with high risk endometrial cancer
P. T. Soliman1, S. N. Westin1, C. C. L. Sun1, S. Dioun2, M. Frumovitz1, A. M. Nick1, N. D. Fleming3, P. T. Ramirez1, C. F. Levenback1 and K. H. Lu1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3The University of Texas, MD Anderson Cancer Center, Houston, TX
 
3:02 PM
A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
D. P. Bender1, M. Sill2, H. Lankes2, C. J. Darus3, J. Delmore4, J. Rotmensch5, H. J. Gray6, R. S. Mannel7, J. M. Schilder8, K. K. Leslie1, H. D. Reyes1, M. Hunter9, C. K. McCourt10 and M. Samuelson1
1University of Iowa Hospitals and Clinics, Iowa City, IA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Maine Medical Partners, Scarborough, ME, 4University of Kansas School of Medicine, Wichita, Wichita, KS, 5Rush University Medical Center, Chicago, IL, 6University of Washington Medical Center, Seattle, WA, 7University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8Indiana University School of Medicine, Indianapolis, IN, 9University of Missouri, Columbia, Columbia, MO, United States, 10Washington University School of Medicine, St Louis, MO
 
3:08 PM
A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study
J. K. Chan1, W. E. Brady2, J. Brown3, M. S. Shahin4, P. G. Rose5, J. H. Kim6, A. A. Secord7, J. L. Walker8 and B. J. Monk9
1California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, 5Cleveland Clinic, Cleveland, OH, 6Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 7Duke University Medical Center, Durham, NC, 8The University of Oklahoma, Oklahoma City, OK, 9Creighton University School of Medicine and University of Arizona Cancer Center at St. Joseph's Hospital, Phoenix, AZ
 
3:14 PM
Impact of NCI Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival
R. E. Bristow1, J. Chang1, A. Ziogas1, B. Campos2, L. R. Chavez2 and H. Anton-Culver3
1University of California, Irvine, Irvine, CA, 2UC Irvine Medical Center, Orange, CA, 3University of California at Irvine, Irvine, CA
 
3:23 PM
Phase III SCORPION trial (ID number: NCT01461850) in epithelial ovarian cancer patients with high tumor load receiving PDS versus NACT: ad interim analysis on peri-operative outcome
A. Fagotti1, G. Vizzielli2, F. Fanfani2, V. Chiantera2, P. A. Margariti2, V. Gallotta2, B. Costantini2, G. Ferrandina2, L. Tortorella2 and G. Scambia2
1St. Maria Hospital, University of Perugia, Terni, Italy, 2Catholic University of the Sacred Heart, Milan, Italy
 
3:32 PM
Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial
N. T. Phippen1, B. A. Davidson2, S. Wolf2, G. Samsa2, D. Cella3, L. J. Havrilesky2, R. A. Burger4, A. A. Secord2, B. J. Monk5 and C. A. Leath III6
1Walter Reed National Military Medical Center, Bethesda, MD, 2Duke University Medical Center, Durham, NC, 3Northwestern University, Chicago, IL, 4University of Pennsylvania, Philadelphia, PA, 5University of Arizona Cancer Center, Phoenix, AZ, 6University of Alabama at Birmingham, Birmingham, AL
 
3:40 PM
Concluding Remarks
D. E. Cohn1 and M. L. Hensley2
1The Ohio State University, Columbus, OH, 2Weill Cornell Medical College, New York, NY
 
See more of: Scientific Plenary
<< Previous Course | Next Course >>